In the northern Netherlands, researchers have made a breakthrough that could transform the lives of thousands of families carrying a rare but devastating genetic mutation. Working with patient-derived heart cells at UMCG, a team led by Dr. Frits Deiman has shown that RNA therapy can reduce the protein clumping that drives PLN cardiomyopathy—and crucially, reverse the cellular damage it causes.
PLN R14del is a Dutch founder variant that emerged in Friesland centuries ago and remains particularly common in the north of the Netherlands today. Though rare in the general population, it is one of the most common genetic causes of inherited cardiomyopathy in the country, accounting for approximately 10 to 15 percent of Dutch patients with dilated or arrhythmogenic cardiomyopathy. The Netherlands now hosts one of the largest known populations of PLN R14del carriers worldwide—a concentration that makes the country uniquely positioned to lead research into precision treatments for this condition.
Until now, doctors have had only one choice: treat the symptoms. Current therapies for PLN cardiomyopathy manage heart failure and prevent complications, but they do not address the genetic cause. The mutant PLN protein builds up inside heart muscle cells, forming toxic aggregates that progressively damage cellular function. Deiman's work explored whether RNA therapy could work differently—by directly silencing the disease-causing gene and preventing those aggregates from forming in the first place.
Using induced pluripotent stem cells derived from patients with the PLN mutation, the researchers tested their approach. The results were striking. After RNA treatment, PLN protein aggregation decreased sharply, and disease-associated abnormalities improved. But understanding why this worked mattered just as much as seeing it work. The team employed phosphoproteomics—a technique that maps the molecular switches controlling cellular signaling—and discovered that the mutation disrupts calcium regulation and heart cell function in predictable, measurable ways. Remarkably, RNA therapy reversed several of these abnormalities, restoring critical processes that the disease had broken.
These findings, published in Signal Transduction and Targeted Therapy, arrive at a pivotal moment. PLN-targeted RNA therapy has recently progressed to early clinical testing in patients with PLN cardiomyopathy. This represents one of the first human trials of RNA therapy designed to directly target the underlying cause of an inherited cardiomyopathy—and it signals the Dutch research community's leading role in advancing precision medicine for genetic heart disease. By revealing how RNA therapy affects the biological mechanisms inside heart muscle cells, these laboratory results provide a roadmap for understanding how genetic treatments will perform in living patients.
The work suggests something profound: that some genetic diseases may soon move from lifelong symptom management into the realm of precision treatment—therapies tailored to fix the exact molecular error that caused the disease in the first place. For the many Dutch families carrying PLN R14del, hope now has a biological basis.